1



Board -2017 -Mtg -1-Doc 12

Section A: Introduction
? This report requests a decision by the Board to extend Gavi?s support for
IPV to the end of 2020 under arrangements agreed by the Board in
November 2013, and subject to sufficient polio -specific funding being made
available . The Programme and Policy Committee ( PPC ) su pported this
proposal at its meeting in May 2017 and requested that Gavi?s longer -term
role in supporting IPV (beyond 2020) be considered as part of the upcoming
Vaccine Investment Strategy (VIS) . This paper is the product of close
collaboration between th e Gavi Secretariat and GPEI.
Section B: Gavi?s Potential Engagment In IPV Post -2018
1.1 In November 2013 the Board decided to support the introduction of
inactivated poliovirus vaccine (IPV) in all 73 Gavi -supported countries as
pa rt of the polio eradication ?E ndgame ? strategy . The Board approved
support until the end of 2018 , which was the projected date of global
certification of polio eradication at the time of the Board decision . Subject to
polio -specific additional funding being available beyo nd 2018, support
would continue until the Endgame target for stopping vaccination of 2024 ,
or an appropriate exit strategy for Gavi had been identified . Three donors to
GPEI (BMGF, UK, Norway) provided US$ 405 million to fund IPV
introduction up to end -2018 1.
1.2 The Board approved a series of policy exceptions to allow for the
unprecedented introduction timeline and other aspects of IPV support that
were different to Gavi? s regular vaccine support . These included waivers to
the policies on country co -financing and country eligibility . The Board
decided that the se policy exceptions would be reviewed in 2018.
1.3 Applications from all 70 IPV -eligible countries were received and approved
for Gavi support within 12 months of the Board decision 2. However, there
have been two significant developments since the n:

1 This is less than the original funding of US$ 430 million due to exchange rate fluctuations (current
funding estimate converted at 28 Feb 2017 FX rate, from GBP (DFID), NOK (Norway) and US$
(BMGF)). 2 India was funded separately , with GPEI providing US$ 3 0.6 million through Gavi for one year of
catalytic vaccine support ending in 2016; Ukraine had introduced IPV in 2006, and Georgia opted
for a combination vaccine not supported by the Alliance.
SUBJECT : GAVI?S POTENTIAL ENGAG EMENT IN IPV POST 2018
Agenda item: 12
Category: For Decision
Report to the Board
14 -15 June 2017

Board -2017 -Mtg -1-Doc 13

Section A: Introduction
? The Managing Director Audit and Investigations is required to report to the
Board at least annually (reports are otherwise made to the Audit and
Finance Committee (?AFC?) on matters arising, typically five times per year,
and ad hoc as required) . This report update s the Board o n the results of the
Audit and Investigations (? A&I ?) activity (summarised in Annex A ) since the
last Board report of June 2016 and is a high level summary of matters
reported to the AFC .
? The Board approved the reconstitution of the audit function from a single
person Internal Audit activity in December 2014 (as part of Gavi?s
enhancement of its risk management activities incorporating the three lines
of defence model, a commonly used configuration of risk management ). A&I
comprises the third line of defen ce being independent of the operational
activities of the first two lines, and re ports to the Board, which is effected
through routine reporting to the A FC , and the Chief Executive Officer. Audit s
are conducted against annual plans approved by the AFC, dra wn from a
risk -based assessment of priority .
? The A&I function was established in February 2015 with a 13 person
authorised headcount. The B oa rd approved the function?s charter of
operation (?Audit and Investigations Terms of Reference? , ToR ), reflecting
th is reconstitution, in December 2015. The A&I function comprises four
main activities:
o Internal Audit which is an independent and objective assurance and
consulting activity to evaluate and improve the effectiveness of the
organisation's risk management, co ntrol, and governance processes .
o Programme Audit which conducts audits of programmes in -country to
assess whether Gavi support, including cash, vaccines and related
supplies, have been used as intended to provide value -for -money,
considering both financial and programmatic aspects.
o Investigations and Counter -Fraud which conducts an evidence -based
examination of possible misuse and other misconduct within Gavi, in
Gavi -supported programmes in -country, or which otherwise impact
upon the organisation. It condu cts preventive activities to minimise the
risk of such conduct occurring and/or impacting the organisation.
SUBJECT : REPORT FROM AUDIT AND INVESTIGATIONS
Agenda item: 13
Category: For Information
Report to the Board
14 -15 June 2017

1



Board -2017 -Mtg -1-Doc 14

Section A: Introduction
? This report provides the Gavi Board with an update on fundraising efforts in
the midst of significant geopolitical changes. It highlights (i) the status of
conversion and payment of the Berlin pledges, and (ii) the efforts being
deployed to broaden both sovereign and private s ector partners .
Section B: Status of fundraising efforts
Securing Berlin outcomes
1.1 Two years following the Berlin pledging conference, grants representing
86 % of the total cash value of pledges announced in Berlin have been
signed (see Figure 1) . All lon g-term pledges including new IFFIm grants
have now been secured. In total, 50 agreements have been signed , which
has involved complex negotiations with various multilateral, bilateral and
innovative finance sources and a variety of development agencies wit h
different requirements and procedures. The remaining pledges are annual
and will need to be signed year -by -year in line with countries ? annual budget
cycle s.
1.2 With elections in donor countries representing nearly two thirds of Gavi
support taking place i n late 2016 and 2017 , these results have required
deepened bi -partisan engagement, continuing advocacy and civil society
dialogue and early engagement with newly -elected governments. In the
midst of shifting global development priorities , competing needs ( e.g.
humanitarian crises and national security) and an increasingly divergent
worldview among donors, it has been particularly important to highlight
Gavi?s flexible, impactful and innovative model and reinforce the link
between immunisation, development and economic growth.



SUBJECT : RESOURCE MOBILISATION UPDATE
Agenda item: 14
Category: For Information
Report to the Board
14 -15 June 2017

1



Board -2016 -Mtg -1-Doc 15
Report to the Board
14 -15 June 201 7

















SUBJECT: REVIEW OF DECISIONS
Agenda item: 15
No paper

1



Board -2016 -Mtg -1-Doc 16
Report to the Board
14 -15 June 201 7

















SUBJECT: CLOSING REMARKS AND R EVIEW OF BOARD
WORKPLAN
Agenda item: 16
No paper

Board -2017 -Mtg -01 1
Minutes



Gavi Alliance Board Meeting
14 -15 June 2017
Intercontinental Hotel, Geneva, Switzerland


1. Chair?s report

1.1 Finding a quorum of members present, the meeting commenced at 09.0 9 local
time on 14 June 2017 . Ngozi Okonjo -Iweala , Board Chair , chaired the meeting .

1.2 The Chair welcomed new Board member s and Alternate Board member s, as well
as Rob Moodie, Chair of the Ev aluation Advisory Committee , and member s of the
IFFIm Board. She noted that departing members would be recognised for their
service at the dinner that evening.

1.3 The Board met in closed session on the evening of 13 June to discu ss a number
of items including Board Leadership, the Geneva Health Campus and a Gavi HR
update .

1.4 Standing declarations of interest were tabled to the Board (Doc 01a in the Board
pack). The Chair noted that in the context of the items for decision on the agenda ,
there were a nu mber of Board member s who would have conflicts of interest and
that these would be raised at the appropriate time and recorded in the applicable
parts of the minutes.

1.5 The Board noted its minutes from 7-8 December 2016 (Doc 01b), which were
approved by no objection on 24 February 2017 . The Board also noted its action
sheet (Doc 01d) and workplan (Doc 01 e) and the Chair encouraged Board
members to contribute to the forward plan by raising issues which they may wish
to add either with her directly or with the Secretariat .

1.6 The Chair noted that while there has been an improvement in the quality and
volume of the papers that are being shared with the Board , she feels that there is
still room to further reduce the volume and perhaps have more summary
documents and she encouraged the Secretariat to continue to work on this.

1.7 The Chair informed Board members that the Executive Committee had not met
since the la st Board meeting , and noted that the Board had approved a decision
by unanimous consent, as outlined in Doc 01c .

1.8 Finally, the Chair shared some thoughts with the Board in relation to the current
global environment and the potential impact on the global development agenda.
In such a context it will be necessary for the Alliance to reflect on the way we do
our work wit h countries, focus on the efficiencies we can get and keep our nose to
the grindstone. She thanked new donors from the Middle East and other areas
who have become recent supporters of Gavi .

Board -201 7-Mtg -1-Doc 00 a



G avi Alliance Board Meeting
14 -15 June 2017
Intercontinental Hotel, Geneva, Switzerland

Monday 12 and Tuesday 13 June: Pre -Board meetings
Wednesday 14 June: 0 9.00 -17.30 (Board meeting Day One)
Thursday 15 June: 09.00 -16.00 (Board meeting Day Two)
Qu orum: 14

Document list

No. Document
00a Document list
00b Agenda
01a Declarations of interest
01b Minutes from 7-8 December 2016
01c Unanimous consent decisions
01 d Action Sheet
01 e Workplan
02a Consent agenda: Board Leadership (To follow)
02b Consent agenda: Board/Committee member appointments (To follow)
02c Consent agenda: Changes to Committee Charters (To follow)
02d Consent agenda: Changes to Statutes and By -Laws (To follow)
02e Consent agenda: Gavi Policy: Fragility, emergencies and re fugees
02f Consent agenda: Review of Cold Chain Equipment Optimisation Platform
02g Consent agenda: Programme Funding Policy (To follow)
03 2016 -2020 Strategy: Implementation and progress
04 CEO?s report (To follow)
05 Financial update
06 Partners? E ngagement Framework
07 a Country Programmes: strategic issues
07b Case study: Alliance partners joining efforts towards improving equitable and
sustainable immunisation coverage in Pakistan
08 Chair?s reflections on the day ? No paper
09 Chair?s overvie w ? No paper
10 Committee Chair and IFFIm Board reports (To follow)

Board -201 7-Mtg -1-Doc 00b




G avi Alliance Board Meeting
14 -15 June 2017
Intercontinental Hotel, Geneva, Switzerland

Monday 12 and Tuesday 13 June : Pre -Board meetings
Wednesday 14 June : 0 9.00 -17.30 (Board meeting Day One)
Thursday 15 June : 0 9.00 -16.00 (Board meeting Day Two)
Qu orum: 14


Agenda REVISED


Pre -Board Meetings ? Monday, 12 June 2017
Item Subject Room Schedule

? IFFIm Donors? meeting Moscou 13. 00 -15.30
? Audit and Finance Committee meeting Gavi Offices, 101 14.00 -18.00
? AMC Stakeholders? meeting Berne 16.00 -18.00


Pre -Board Meetings ? Tuesday , 13 June 2017
Item Subject Room Schedule

? Technical Briefing Session s
o Vaccine investment strategy
Break
o Immunisation in humanitarian settings
Ballroom AE 09.00 -12.30
09.00 -10. 30

11.00 -12.30
? Governance Committ ee meeting Londres 11.00 -13.00
Lunch Ballroom BC/
Foyer D
12. 30 -13. 30
? Technical Briefing Sessions (contd.)
o Health, climate change and environmental
impact of immunisation
Berne 13. 00 -14.30
13. 00 -14.30
? Developing Countries Board members meeting Ballro om AE 14.00 -15. 30
? All Chairs meeting Bruxelles 14. 30 -15. 30
? IFFIm Board meeting Moscou 15.30 -19.00
? Board Meeting: Closed session for Board
members and Alternate Board members
Ballroom AE 16.00 -19.00
? Unaffiliated Board members meeting Woods 19.15 -20. 15
? Gavi Donors? meeting Berne 19. 30 -21. 30

Board -201 7-Mtg -1-Doc 01 a



Gavi Alliance Board Meeting
14 -15 June 201 7
Intercontinental Hotel, Geneva, Switzerland

Quorum: 14
Declarations of Interest

Declarations
Section 5.2 of the Conflict of Interest Policy states, ?Annually, each member of the Board
(including a lternate Board members and Committee delegates)...shall complete and submit a
conflict of interest form to be distributed by the Managing Director, Law and Governance.? The
following declarations were made by members of the Board on their most recent annu al
statements:
Board members:
Member Org anisational Interest s

Financial/Personal/Advisor Int /
Others
Ngozi Okonjo -Iweala , Chair None Gavi -appointed special adviser
Flavia Bustreo, Vice Chair WHO Gavi -appointed special adviser
Gunilla Carlsson None
Gen eva Center Security Policy
(Associate Fellow)
ADB (Special Advisor)
Annexin Pharmaceuticals AB
(Board)
NGS Group AB (Board)
Boxholms Sk rgar AB (Board)
Kolmarden Charity (Board Chair)
Tundra (Board)
Peggy Hamburg None
Joint Coordinating Group (Chair)
Coali tion for Epidemic Innovations
(CEPI) (Board)
Yifei Li None
Man Group (Country Chair)
Rockefeller Foundation (Board)
Jackson Institute for Global
Affairs, Yale University (Board)
Helen Rees None None
William H. Roedy None None
Richard Sezibera None Gavi -appointed special adviser
David Sidwell None
Chubb Limited (Board)
UBS (Board, Risk and
Governance Committees)
Stephen Zinser None Roxbury Asset Management
(CEO and Co -CIO)
Orin Levine Bill & Melinda Gates Foundation PATH ( Spouse )
Tim Evans The World Bank None

Board -2016 -Mtg -02 1
Minutes



Gavi Alliance Board Meeting
7-8 December 2016
Sofitel Abidjan Hotel Ivoire, Abidjan, C ?te d?Ivoire


1. Chair?s report

1.1 Finding a quorum of members present, the meeting commenced at 09.19 local
time on 7 December 201 6. Ngozi Okonjo -Iweala , Board Chair , chaired the
meeting .

1.2 The Chair welcomed new Board member s and Alternate Board member s, as well
as Rob Moodie, Chair of the Evaluation Advisory Committee . She shared regrets
from Ren? Karsenti, Chair of the IFFIm Board, who had been unable to attend due
to other commitments. She noted that departing members would be recognised
for their service at the dinner that evening.

1.3 The Board met in closed session on the evening of 6 December and the morning
of 7 December to discu ss a number of items including potential Gavi engagement
in Syria, the Board an d Committee self -evaluation and to review the CEO ?s
performance.

1.4 Standing declar ations of interest were tabled to the Board (Doc 01a in the Board
pack). The Chair noted that in the context of the items for decision on the agenda ,
there were a number of Board member s who would have conflicts of interest and
that these would be raised at the appropriate time and recorded in the applicable
parts of the minutes.

1.5 The Board noted its minutes from 22 -23 June 2016 (Doc 01b), which were
approved by no objection on 22 September 201 6. The Board also noted its
workplan (Doc 01c) and the Chair e ncouraged Board members to contribute to the
forward plan by raising issues which they may wish to add either with her directly
or with the Secretariat . She had solicited inputs to the agenda for this meeting but
had only received two responses. It is plan ned that further work will be done to
identify the best process for eliciting input of Board members.

1.6 The Chair informed Board members that the Secretariat continues to work on the
quality of the Board meeting materials and that the e xecutive summaries for the
papers requiring decisions continue to be condensed and are easier to read.
Considerable additional material related to the topics on the agenda can be
access ed on myGavi for those wishing to receive more comprehensive
informatio n.

1.7 Finally, the Chair informed Board members that the Executive Committee had only
met once since the last Board meeting, on 1 November 2016, to consider a
commercially sensitive decision regarding a rotavirus vaccine.

1



Board -2017 -Mtg -1-Doc 01c
Report to the Board
14 -15 June 201 7


Since the December 2016 Board meeting, one decision has been circulated to the
Board electronically for approval by unanimous consent in line with Article 2.7.3.1
of the By -Laws.

On 13 March 2017, Board members were invited to consider the following:

The Gavi Alliance Board:

(a) Approved that the transitioned countries who have already been approved
for an HPV National introduction (i.e. Bolivia, Guyana, Honduras and Sri
Lanka) can apply for support for multi -age cohort HPV vaccinations (9 -14
years of age) in year one of introduction of t he vaccine, including support
for 50% of vaccine costs for the additional cohorts as well as operational
costs of US$ 0.45 per girl targeted.

(b) Noted that the funding associated with the above approval for the period
2017 -2020 is expected to be approximatel y US$ 3 million and will be allotted
to individual programmes from the Programme Funding Envelope approved
by the Board for each year, in accordance with the Programme Funding
Policy.

On 22 March 2017, c onsent to the decision had been received from all vo ting
me mbers of the Board and it was therefore considerd a pproved by unanimous
consent, and Board members informed accordingly .

In line with the Gavi Conflict of Interest Policy, Dr Yolani Batres (Honduras)
recused herself from voting on the decision. Her Alternate Board member, Dr
Sergey Khachatryan (Armenia) voted on behalf of their constituency.
SUBJECT: UNANIMOUS CONSENT DE CISIONS
Agenda item: 01c
Category: For information

Board -2017 -Mtg -1-Doc 01 d 1




G avi Alliance Board

Action sheet as of 31 May 2017

Request Matter Responsible Action taken

22 -23 June
2016
? 4
CEO?s report :
? Request for a pre -Board technical
briefing session on CSO?s role in
contributing to coverage and
equity

Secretar iat
(Armstrong )

Combined with
June 2017
session on
immunisation in
humanitarian
settings

22 -23 June
2016
? 4
CEO?s report:
? Ensure that risk is a standing item
on the agenda for all Board
meetings going forward

Secretariat
(Armstrong)
Included as a
stan ding item
on Board
workplan

22 -23 June
2016
? 13
Partners? Engagement Framework
& Alliance Accountability
Framework:
? Comparison of PEF with old
business plan

Secretariat
(Gupta/De
Chaisemartin)

Will be
addressed as
part of the
prospective
evaluation of
Technical
Assistance (TA)


7-8
December
2016 ? 3
2016 -2020 Strategy:
Implementation and progress :
? Sustainability to be included as a
topic for discussion at the Board
Retreat in April 2017

Secretariat
(Armstrong)

Was discussed
at 2017 Board
Retreat

7-8
December
201 6 ? 4
CEO?s report:
? Board to do a deep dive on one or
two countries to better understand
how the Alliance works in -country

Secretariat &
Alliance

Deep dive on
Nigeria and
PNG at Oct
2017 PPC an d
Nov 2017
Board in the
context of the
develo pment of
country -specific
strategies (for
approval in
Spring 2018)